Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Pfizer Inc (PFE) is a leading drug manufacturers-general business based in the US. It opened the day at $54.98 after a previous close of $55.54. During the day the price has varied from a low of $54.51 to a high of $55.38. The latest price was $54.95 (25 minute delay). Pfizer is listed on the NYSE and employs 78,500 staff. All prices are listed in US Dollars.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Open | $54.98 |
|---|---|
| High | $55.38 |
| Low | $54.51 |
| Close | $54.95 |
| Previous close | $55.54 |
| Change | $-0.59 |
| Change % | -1.0623% |
| Volume | 27,072,545 |
| 52-week range | $32.45 - $61.71 |
|---|---|
| 50-day moving average | $53.84 |
| 200-day moving average | $44.79 |
| Wall St. target price | $54.51 |
| PE ratio | 15.6655 |
| Dividend yield | $1.55 (2.82%) |
| Earnings per share (TTM) | $3.50 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $54.95 from 2022-01-20
| 1 week (2022-01-14) | 54.95 |
|---|---|
| 1 month (2021-12-17) | -7.62% |
| 3 months (2021-10-21) | 28.21% |
| 6 months (2021-07-21) | 33.96% |
| 1 year (2021-01-21) | 50.63% |
|---|---|
| 2 years (2020-01-21) | 36.22% |
| 3 years (2019-01-18) | 29.20% |
| 5 years (2017-01-20) | 72.96% |
Valuing Pfizer stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pfizer's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pfizer's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, Pfizer shares trade at around 16x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Pfizer's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.601. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Pfizer's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Pfizer's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $27.3 billion.
The EBITDA is a measure of a Pfizer's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $69.3 billion |
|---|---|
| Operating margin TTM | 32.14% |
| Gross profit TTM | $33.3 billion |
| Return on assets TTM | 7.78% |
| Return on equity TTM | 27.75% |
| Profit margin | 28.68% |
| Book value | $13.49 |
| Market capitalisation | $307.8 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Pfizer.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 33.15
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Pfizer's overall score of 33.15 (as at 12/31/2018) is pretty weak – landing it in it in the 60th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Pfizer is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 7/100
Pfizer's environmental score of 7 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Pfizer is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 18.47/100
Pfizer's social score of 18.47 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Pfizer is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 13.68/100
Pfizer's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Pfizer is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Pfizer scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Pfizer hasn't always managed to keep its nose clean.
Pfizer Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 33.15 |
|---|---|
| Total ESG percentile | 60 |
| Environmental score | 7 |
| Environmental score percentile | 6 |
| Social score | 18.47 |
| Social score percentile | 6 |
| Governance score | 13.68 |
| Governance score percentile | 6 |
| Level of controversy | 3 |
Dividend payout ratio: 41.76% of net profits
Recently Pfizer has paid out, on average, around 41.76% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.82% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Pfizer shareholders could enjoy a 2.82% return on their shares, in the form of dividend payments. In Pfizer's case, that would currently equate to about $1.55 per share.
While Pfizer's payout ratio might seem fairly standard, it's worth remembering that Pfizer may be investing much of the rest of its net profits in future growth.
Pfizer's most recent dividend payout was on 3 March 2022. The latest dividend was paid out to all shareholders who bought their shares by 26 January 2022 (the "ex-dividend date").
Pfizer's shares were split on a 1054:1000 basis on 16 November 2020. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1054 shares. This wouldn't directly have changed the overall worth of your Pfizer shares – just the quantity. However, indirectly, the new 5.1% lower share price could have impacted the market appetite for Pfizer shares which in turn could have impacted Pfizer's share price.
Over the last 12 months, Pfizer's shares have ranged in value from as little as $32.4531 up to $61.71. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Pfizer's is 0.6427. This would suggest that Pfizer's shares are less volatile than average (for this exchange).
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
Everything we know about the HeartCore Enterprises IPO, plus information on how to buy in.
Everything we know about the Credo Technology Group Holding IPO, plus information on how to buy in.
Everything we know about the Hongli Group IPO, plus information on how to buy in.
Everything we know about the Reborn Coffee IPO, plus information on how to buy in.